Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,450 restricted stock units (RSUs) to two newly hired employees, effective Feb 28, 2026, under its 2022 Inducement Stock Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

Each RSU vests over three years with 33 1/3% vesting on each consecutive anniversary and is contingent on continued service through each vesting date.

Key Figures

Inducement RSUs granted: 1,450 RSUs New employees: 2 employees Vesting period: 3 years +2 more

5 metrics

Inducement RSUs granted 1,450 RSUs Aggregate awards to two newly hired employees as of Feb 28, 2026

New employees 2 employees Recipients of inducement RSU awards under 2022 Inducement Plan

Vesting period 3 years RSUs vest in three equal annual installments from Grant Date

Annual vesting fraction 33 1/3% Portion of RSU award vesting on each of three anniversaries

Grant Date February 28, 2026 Effective date of the inducement RSU awards

Market Reality Check

Price: $9.59 Vol: Volume 529,768 is below 2...

normal vol

$9.59 Last Close

Volume Volume 529,768 is below 20-day average of 712,150 (relative volume 0.74x). normal

Technical Trading above 200-day MA, with price at $9.41 versus 200-day MA of $5.92.

Peers on Argus

KPTI was up 0.64% while only one momentum peer (MAIA) appeared, moving down 0.72...

1 Down

KPTI was up 0.64% while only one momentum peer (MAIA) appeared, moving down 0.72% with no news, indicating stock-specific trading rather than a coordinated sector move.

Historical Context

5 past events · Latest: Feb 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 12	Earnings and guidance	Neutral	+21.3%	Full-year 2025 results, 2026 revenue guidance, and upcoming Phase 3 data.
Feb 05	Earnings date notice	Neutral	-3.3%	Announcement of timing and access details for Q4 and 2025 results call.
Feb 02	Inducement RSU grants	Neutral	+3.8%	Grant of 1,799 RSUs to new hires under 2022 Inducement Plan.
Jan 12	Clinical and revenue update	Negative	-5.6%	Preliminary 2025 revenue, limited cash runway, Phase 3 data timelines.
Jan 02	Inducement RSU grants	Neutral	+2.9%	Grant of 1,533 RSUs to new hires with three-year vesting schedule.

Pattern Detected

Recent history shows larger moves around earnings and liquidity updates, while prior inducement grant announcements produced modest positive reactions despite neutral fundamentals.

Recent Company History

Over the last few months, Karyopharm combined recurring inducement RSU grants with major financial and clinical updates. The Feb 12 earnings release highlighted $146.1M 2025 revenue, sizable losses, and key Phase 3 data expected in March 2026 and mid‑2026, and the stock gained 21.3%. Earlier, a Jan 12 update on preliminary 2025 revenue, limited liquidity into the second quarter of 2026, and late‑stage trial milestones saw a -5.59% move. Inducement grant press releases on Jan 2 and Feb 2 generated smaller positive reactions, providing context for today’s similar RSU announcement.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-11-03

An effective S-3 resale registration filed on Nov 3, 2025 covers up to 2,805,688 shares of common stock held or issuable to selling stockholders, including 1,487,917 outstanding shares and 1,317,771 warrant shares. The company is not selling securities in this registration and receives cash only if warrants are exercised. The filing has seen 2 related 424B3 usage events.

Market Pulse Summary

This announcement details a small inducement grant of 1,450 RSUs to two new employees under the 2022...

Analysis

This announcement details a small inducement grant of 1,450 RSUs to two new employees under the 2022 Inducement Stock Incentive Plan, vesting over three years in equal installments from a February 28, 2026 Grant Date. It follows similar RSU inducement releases in January and early February 2026. Against a backdrop of substantial 2025 losses, limited liquidity into the second quarter of 2026, increased authorized share capital, and an active S-3 resale registration, investors may monitor how ongoing equity-based compensation interacts with the company’s broader capital structure.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

4 terms

restricted stock units financial

"granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"1,450 restricted stock units (RSUs) to two newly-hired employees. These RSU awards"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. Not financial advice.

NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of February 28, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302696414.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

How many RSUs did Karyopharm (KPTI) grant on Feb 28, 2026 and to whom?

Karyopharm granted 1,450 RSUs in aggregate to two newly hired employees. According to the company, the awards were issued as inducements under its 2022 Inducement Stock Incentive Plan to secure new hires in accordance with Nasdaq rule 5635(c)(4).

What is the vesting schedule for the KPTI RSU awards granted Feb 28, 2026?

Each RSU award vests over three years with 33 1/3% vesting each anniversary. According to the company, vesting occurs on each of the three consecutive anniversaries of the Feb 28, 2026 grant date, subject to continued service.

Why did Karyopharm (KPTI) use an inducement grant under Nasdaq Listing Rule 5635(c)(4)?

Karyopharm used an inducement grant to onboard new employees with equity incentives outside existing equity plans. According to the company, this complies with Nasdaq Listing Rule 5635(c)(4) for grants material to hiring new personnel.

Will the KPTI RSU grants immediately dilute existing shareholders?

The RSUs represent potential future dilution only when vested and settled; they do not cause immediate share issuance. According to the company, each award vests over three years and requires continued service before shares are issued.

Where can investors find details about Karyopharm's 2022 Inducement Stock Incentive Plan and these grants?

Investors can review plan terms and grant specifics in company filings and disclosures. According to the company, the awards were granted under the 2022 Inducement Stock Incentive Plan and described in the March 2, 2026 announcement.